

Kayentis

Global provider of eCOA and patient-centric solutions

//COAs white paper// Why are they important criteria in the evaluation of dossiers by health authorities?


kayentis · Wednesday, December 7th, 2016

Diverse elements have combined in recent years to make Clinical Outcome Assessments (COAs), and particularly Patient Reported Outcomes (PROs), important criteria for various health authorities in the evaluation of new therapeutic strategies. So Olivier Chassany has written this COAs white paper in order to deal with their importance in the evaluation by health authorities.

Why is this and what are the consequences for evaluation of new drugs in clinical development programs? When should COA endpoints be considered for inclusion in a new drug development program?

By [Olivier Chassany](#), Professor of PROs & Clinical Endpoints research at the University Paris-Diderot, France

TO READ THE WHITE PAPER, CLICK BELOW :



This entry was posted on Wednesday, December 7th, 2016 at 3:25 pm and is filed under [Optimizing clinical trials](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.